A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome

Nature Genetics

Volumn 45, Issue 9, 2013, Pages 1013-1020

  Buchovecky, Christie M ^a   Turley, Stephen D ^b   Brown, Hannah M ^a,e   Kyle, Stephanie M ^a   McDonald, Jeffrey G ^b   Liu, Benny ^b   Pieper, Andrew A ^b,e,f   Huang, Wenhui ^c,e,g   Katz, David M ^d   Russell, David W ^b   Shendure, Jay ^c   Justice, Monica J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF IOWA   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ETHYLNITROSOUREA; GENOMIC DNA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYL CPG BINDING PROTEIN 2; SQUALENE MONOOXYGENASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN TISSUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHROMOSOME 15; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENETIC LINKAGE; HERITABILITY; INFLAMMATION; LETHARGY; LIVER; LONGEVITY; MALE; MALOCCLUSION; MOUSE; MUTAGENESIS; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RETT SYNDROME; STOP CODON; SURVIVAL RATE; TREMOR;

ANIMALS; BEHAVIOR, ANIMAL; CHOLESTEROL; CHROMOSOME MAPPING; CODON, TERMINATOR; DISEASE MODELS, ANIMAL; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, KNOCKOUT; MUTATION; QUANTITATIVE TRAIT LOCI; RETT SYNDROME;

MUS;

EID: 84883390784     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2714     Document Type: Article

References (63)

1. Amir, R.E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
2. Bienvenu, T. & Chelly, J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Natl. Rev. Genet. 7, 415-426 (2006).
3. Guy, J., Hendrich, B., Holmes, M., Martin, J.E. & Bird, A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322-326 (2001).
4. Shepherd, G.M. & Katz, D.M. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr. Opin. Neurobiol. 21, 827-833 (2011).
5. Kavalali, E.T., Nelson, E.D. & Monteggia, L.M. Role of MeCP2, DNA methylation, and HDACs in regulating synapse function. J. Neurodev. Disord. 3, 250-256 (2011).
6. Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007).
7. Collins, A.L. et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679-2689 (2004).
8. Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008).
9. Stancheva, I., Collins, A.L., Van den Veyver, I.B., Zoghbi, H. & Meehan, R.R. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos. Mol. Cell 12, 425-435 (2003).
10. St Johnston, D. The art and design of genetic screens: Drosophila melanogaster. Nature Rev. Genet. 3, 176-188 (2002).
11. Carpinelli, M.R. et al. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc. Natl. Acad. Sci. USA 101, 6553-6558 (2004).
12. Matera, I. et al. A sensitized mutagenesis screen identifies Gli3 as a modifier of Sox10 neurocristopathy. Hum. Mol. Genet. 17, 2118-2131 (2008).
13. Justice, M.J., Siracusa, L.D. & Stewart, A.F. Technical approaches for mouse models of human disease. Dis. Model. Mech. 4, 305-310 (2011).
14. Derecki, N.C. et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105-109 (2012).
15. Neuhaus, I.M. & Beier, D.R. Efficient localization of mutations by interval haplotype analysis. Mamm. Genome 9, 150-154 (1998).
16. Moran, J.L. et al. Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse. Genome Res. 16, 436-440 (2006).
17. Fairfield, H. et al. Mutation discovery in mice by whole exome sequencing. Genome Biol. 12, R86 (2011).
18. Jurevics, H.A., Kidwai, F.Z. & Morell, P. Sources of cholesterol during development of the rat fetus and fetal organs. J. Lipid Res. 38, 723-733 (1997).
19. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201 (2008).
20. Gill, S., Stevenson, J., Kristiana, I. & Brown, A.J. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab. 13, 260-273 (2011).
21. Cory, E.J., Russey, W.E. & Ortiz de Montellano, P.R. 2,3-oxidosqualene, an intermediate in the biological synthesis of sterols from squalene. J. Am. Chem. Soc. 88, 4750-4751 (1966).
22. Yamamoto, S. & Bloch, K. Studies on squalene epoxidase of rat liver. J. Biol. Chem. 245, 1670-1674 (1970).
23. Shibata, N. et al. Supernatant protein factor, which stimulates the conversion of squalene to lanosterol, is a cytosolic squalene transfer protein and enhances cholesterol biosynthesis. Proc. Natl. Acad. Sci. USA 98, 2244-2249 (2001).
24. Astruc, M., Tabacik, C., Descomps, B. & de Paulet, A.C. Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues. Biochim. Biophys. Acta 487, 204-211 (1977).
25. Ingham, P.W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog signalling across the metazoa. Natl. Rev. Genet. 12, 393-406 (2011).
26. Posé, D. & Botella, M.A. Analysis of the Arabidopsis dry2/sqe1-5 mutant suggests a role for sterols in signaling. Plant Signal. Behav. 4, 873-874 (2009).
27. Posé, D. et al. Identification of the Arabidopsis dry2/sqe1-5 mutant reveals a central role for sterols in drought tolerance and regulation of reactive oxygen species. Plant J. 59, 63-76 (2009).
28. Nieweg, K., Schaller, H. & Pfrieger, F.W. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109, 125-134 (2009).
29. Dietschy, J.M., Turley, S.D. & Spady, D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34, 1637-1659 (1993).
30. Dietschy, J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 390, 287-293 (2009).
31. Russell, D.W., Halford, R.W., Ramirez, D.M., Shah, R. & Kotti, T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 78, 1017-1040 (2009).
32. Chen, R.Z., Akbarian, S., Tudor, M. & Jaenisch, R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327-331 (2001).
33. Pfrieger, F.W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 50, 357-371 (2011).
34. Xie, C., Lund, E.G., Turley, S.D., Russell, D.W. & Dietschy, J.M. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 44, 1780-1789 (2003).
35. Ko, M. et al. Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. J. Biol. Chem. 280, 42759-42765 (2005).
36. Jolley, C.D., Dietschy, J.M. & Turley, S.D. Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am. J. Physiol. 276, G1117-G1124 (1999).
37. Bellosta, S., Paoletti, R. & Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50-III57 (2004).
38. García-Sabina, A., Gulin-Davila, J., Sempere-Serrano, P., Gonzalez-Juanatey, C. & Martinez-Pacheco, R. Specific considerations on the prescription and therapeutic interchange of statins. Farm. Hosp. 36, 97-108 (2012).
39. Osterweil, E.K. et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243-250 (2013).
40. Ardern-Holmes, S.L. & North, K.N. Therapeutics for childhood neurofibromatosis type 1 and type 2. Curr. Treat. Options Neurol. 13, 529-543 (2011).
41. Keber, R. et al. Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14α-demethylase (Cyp51) resembles Antley-Bixler syndrome. J. Biol. Chem. 286, 29086-29097 (2011).
42. Waterham, H.R. Defects of cholesterol biosynthesis. FEBS Lett. 580, 5442-5449 (2006).
43. Björkhem, I. & Hansson, M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46-49 (2010).
44. Lund, E.G. et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980-22988 (2003).
45. Lioy, D.T. et al. A role for glia in the progression of Rett's syndrome. Nature 475, 497-500 (2011).
46. Vance, J.E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Model. Mech. 5, 746-755 (2012).
47. Paolicelli, R.C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456-1458 (2011).
48. Cibickova, L. Statins and their influence on brain cholesterol. J. Clin. Lipidol. 5, 373-379 (2011).
49. Stranahan, A.M., Cutler, R.G., Button, C., Telljohann, R. & Mattson, M.P. Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. J. Neurochem. 118, 611-615 (2011).
50. Day, C.P. & James, O.F. Steatohepatitis: a tale of two "hits?". Gastroenterology 114, 842-845 (1998).
51. Fyffe, S.L. et al. Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress. Neuron 59, 947-958 (2008).
52. Percy, A.K. Rett syndrome: exploring the autism link. Arch. Neurol. 68, 985-989 (2011).
53. Lyst, M.J. et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT transcriptional co-repressor. Nat. Neurosci. 16, 898-902 (2013).
54. Ebert, D.H. et al. Activity-dependent phosphorylation of MECP2 threonine 308 regulates interaction with NcoR. Nature published online; doi:10.1038/nature12348 (16 June 2013).
55. Knutson, S.K. et al. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 27, 1017-1028 (2008).
56. Sun, Z. et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18, 934-942 (2012).
57. Feng, D. et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331, 1315-1319 (2011).
58. Kile, B.T. et al. Functional genetic analysis of mouse chromosome 11. Nature 425, 81-86 (2003).
59. McDonald, J.G., Smith, D.D., Stiles, A.R. & Russell, D.W. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J. Lipid Res. 53, 1399-1409 (2012).
60. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔC(T) method. Methods 25, 402-408 (2001).
61. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
62. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
63. Broman, K.W., Wu, H., Sen, S. & Churchill, G.A. R/qtl: QTL mapping in experimental crosses. Bioinformatics 19, 889-890 (2003).